title: Efficacy and safety of statin and fibrate combination therapy in lipid management.
abstract: Adequate control of hyperlipidemia is of paramount importance for prevention of vascular events. Statins and fibrates are well established treatments for hyperlipidemia. Combination therapy with a statin and fibrate offers significant therapeutic advantage for the treatment of severe or refractory mixed hyperlipidemia. Although such a combination does increase the risk of myopathy, with an incidence of approximately 0.12%, this small risk of myopathy rarely outweighs the established morbidity and mortality benefits of achieving lipid goals. Nevertheless, a higher incidence of myopathy has been reported with statin monotherapy. Statin+fibrate therapy should be considered if monotherapy or adding other drugs (e.g. cholesterol absorption inhibitors, omega-3 fatty acids or nicotinic acid) did not achieve lipid targets or is impractical. The current article focuses on recent studies highlighting the beneficial effects of this combination.
authors.affiliation: Department of Endocrinology, Medwin Hospital, Hyderabad, Andhra Pradesh, India. hidocsunil@ibibo.com
authors.forename: Sunil Kumar
authors.initials: SK
authors.lastname: Kota
authors.forename: Lalit Kumar
authors.initials: LK
authors.lastname: Meher
authors.forename: Epari Sanjeeva
authors.initials: ES
authors.lastname: Rao
authors.forename: Sruti
authors.initials: S
authors.lastname: Jammula
authors.forename: Kirtikumar D
authors.initials: KD
authors.lastname: Modi
mesh_terms: D000924:Anticholesteremic Agents / Q000494:pharmacology; D000069059:Atorvastatin; D004359:Drug Therapy, Combination; D005260:Female; D011345:Fenofibrate / Q000494:pharmacology*; D006538:Heptanoic Acids / Q000494:pharmacology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008297:Male; D009135:Muscular Diseases / Q000097:blood / Q000188:drug therapy* / Q000517:prevention & control; D011758:Pyrroles / Q000494:pharmacology*; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D011758:Pyrroles; D000069059:Atorvastatin; D011345:Fenofibrate